galactose has been researched along with amphotericin b, deoxycholate drug combination in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghamolla, T; Bacher, J; Hope, WW; Petraitiene, R; Petraitis, V; Walsh, TJ | 1 |
| Barnes, R; Bow, E; Charbonneau, C; Earnshaw, S; Herbrecht, R; Kantecki, M; Maertens, J; McDade, C; Morrissey, O; Schlamm, H; Slavin, M; Weinstein, D | 1 |
2 other study(ies) available for galactose and amphotericin b, deoxycholate drug combination
| Article | Year |
|---|---|
The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillus fumigatus; beta-Glucans; Deoxycholic Acid; Drug Combinations; Galactose; Invasive Pulmonary Aspergillosis; Mannans; Proteoglycans; Rabbits | 2010 |
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Cost Savings; Decision Trees; Deoxycholic Acid; Drug Combinations; Echinocandins; Febrile Neutropenia; Galactose; Health Care Costs; Health Resources; Humans; Immunocompromised Host; Lipopeptides; Mannans; Survival Rate; Voriconazole | 2015 |